

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Qianhai Health Holdings Limited

前海健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 911)

POSITIVE PROFIT ALERT

This announcement is made by board (the “**Board**”) of directors (the “**Directors**”) of the Qianhai Health Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Board wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the preliminary review of the Group’s unaudited management accounts for the six months ended 30 June 2024 (the “**Period**”) (the “**Management Accounts**”), and information currently available to the Board, the Group is expected to record a net profit attributable to the Shareholders of approximately HK\$ 15 million (the “**Expected Profit**”), which represent a turnaround from the loss of approximately HK\$112 million recorded for the six months ended 30 June 2023 (the “**Prior Period**”).

The turnaround from loss to profit for the Period was mainly attributable to the combined effect of (i) the turnaround from gross loss of the Prior Period to gross profit for the Period driven by an increase in the average market selling price of semi-conductors, coupled with the Group’s strategic shift towards selling higher-margin product mix; (ii) no additional provision for inventory was recognised in the Period, compared to the provision of HK\$113 million recorded in the Prior Period; and (iii) net of recognition of provision for provision of onerous contracts for purchasing the electronic components products of approximately HK\$20 million in the Period.

The Company is still in the process of finalising its unaudited consolidated results for the Period. The information contained in this announcement is only a preliminary assessment by the Board based on the Management Accounts and the latest information currently available, which have not been reviewed by the audit committee of the Company and may be subject to adjustments. In particular, the exact amount of provision for inventory and the onerous contracts to be recognised for the Period is subject to the subsequent selling price and/or market price of the inventory of the Group as at the date of the interim results announcement of the Company. Actual financial results for the Period may be different from what is disclosed in this announcement. Further details of the Group's financial results and performance will be disclosed in the Company's interim results announcement which is expected to be published in August 2024 in accordance with the requirements of the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Qianhai Health Holdings Limited
Huang Zhiqun
Chairman

Hong Kong, 23 July 2024

As at the date of this announcement, the non-executive Directors are Mr. Huang Zhiqun, Mr. Lim Tzea, Mr. Chen Kaiben and Mr. Chen Qi; the executive Director is Mr. Chen Li Kuang and the independent non-executive Directors are Mr. Li Wei, Mr. Yuen Chee Lap Carl and Mr. Leung Chun Tung.